You are here

  • Home
  • Archive
  • Volume 88, Issue 5
  • Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

Article info

Article menu
Download PDFPDF
Poster Abstracts
Abstracts
62
Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

Authors

Citation

Goadsby PJ, Reuter U, Bonner J, et al
Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial
Journal of Neurology, Neurosurgery & Psychiatry 2017;88:e1.

Publication history

  • First published May 8, 2017.
Online issue publication 
May 08, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/